Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › TX › Hurst › NPI 1003246299
Physician

Texas Pain Relief Group PLLC

Texas Pain Relief Group PLLC was paid $507K by Medicaid between Mar 2020 and Dec 2024, across 25 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 52% of everything it billed.

33Billing provider infoTEXAS PAIN RELIEF GROUP PLLC
HURST, TX 76054
33aNPI1003246299assigned 11/25/2013
28Total paid$507K
24GClaims21,503
24DCodes billed25
24AFirst – last monthMar 2020 – Dec 2024
Compared with peers

Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in Texas

Rank by total paid#3 of 24
Median peer was paid$6K
This provider vs. median86×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official GARI, TRACIE controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$10K$20K$30K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20201,091$1K
20213,288$34K
20225,464$128K
20236,560$194K
2024incomplete5,100$149K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 52% 11,229 10,038 $263K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 15% 3,736 3,539 $76K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 14% 3,842 3,532 $73K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 9.3% 510 477 $47K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 5.5% 540 517 $28K
99203 Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity 1.0% 128 125 $5K
99215 Doctor's office visit, returning patient (complex)Prolong outpt/office vis <1% 32 32 $2K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 34 33 $2K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 54 52 $2K
83992 <1% 161 158 $1K
99205 Prolong outpt/office vis <1% 13 13 $1K
80356 <1% 162 159 $961.00
13 more codes
80324 <1% 162 $916.05
80369 <1% 151 $750.24
80353 <1% 162 $737.80
80360 <1% 159 $642.96
80359 <1% 161 $608.30
80361 <1% 72 $477.36
80365 <1% 75 $414.75
80362 <1% 60 $322.80
80348 <1% 12 $76.56
80346 <1% 12 $75.36
80354 <1% 12 $71.40
80358 <1% 12 $61.44
80373 <1% 12 $57.60

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGARI, TRACIE (CHIEF ADMINISTRATIVE OFFICER)
Same official

Other billing entities under GARI, TRACIE

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.